CA2642744C - Method and composition for treating chronic obstructive pulmonary disease - Google Patents

Method and composition for treating chronic obstructive pulmonary disease Download PDF

Info

Publication number
CA2642744C
CA2642744C CA2642744A CA2642744A CA2642744C CA 2642744 C CA2642744 C CA 2642744C CA 2642744 A CA2642744 A CA 2642744A CA 2642744 A CA2642744 A CA 2642744A CA 2642744 C CA2642744 C CA 2642744C
Authority
CA
Canada
Prior art keywords
compound
composition
chronic obstructive
obstructive pulmonary
ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2642744A
Other languages
English (en)
French (fr)
Other versions
CA2642744A1 (en
Inventor
Ryuji Ueno
Sachiko Kuno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of CA2642744A1 publication Critical patent/CA2642744A1/en
Application granted granted Critical
Publication of CA2642744C publication Critical patent/CA2642744C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2642744A 2006-02-28 2007-02-27 Method and composition for treating chronic obstructive pulmonary disease Expired - Fee Related CA2642744C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77694306P 2006-02-28 2006-02-28
US60/776,943 2006-02-28
PCT/JP2007/054127 WO2007102446A2 (en) 2006-02-28 2007-02-27 Method and composition for treating chronic obstructive pulmonary disease

Publications (2)

Publication Number Publication Date
CA2642744A1 CA2642744A1 (en) 2007-09-13
CA2642744C true CA2642744C (en) 2015-02-24

Family

ID=38462529

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2642744A Expired - Fee Related CA2642744C (en) 2006-02-28 2007-02-27 Method and composition for treating chronic obstructive pulmonary disease

Country Status (13)

Country Link
US (1) US20070203228A1 (cg-RX-API-DMAC10.html)
EP (1) EP1988905B1 (cg-RX-API-DMAC10.html)
JP (2) JP5377970B2 (cg-RX-API-DMAC10.html)
KR (1) KR101409706B1 (cg-RX-API-DMAC10.html)
CN (1) CN101432002B (cg-RX-API-DMAC10.html)
AR (1) AR059636A1 (cg-RX-API-DMAC10.html)
AU (1) AU2007223469B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0708362A2 (cg-RX-API-DMAC10.html)
CA (1) CA2642744C (cg-RX-API-DMAC10.html)
MX (1) MX2008011148A (cg-RX-API-DMAC10.html)
NZ (1) NZ571092A (cg-RX-API-DMAC10.html)
TW (1) TWI422368B (cg-RX-API-DMAC10.html)
WO (1) WO2007102446A2 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5377970B2 (ja) * 2006-02-28 2013-12-25 スキャンポ・アーゲー 慢性閉塞性肺疾患を処置するための方法および組成物
WO2011072383A1 (en) * 2009-12-18 2011-06-23 Apotex Pharmachem Inc. Processes for the purification of lubiprostone
AU2012246999A1 (en) * 2011-04-19 2013-10-17 Sucampo Ag Method for modulating cytokine activity
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362751A (en) * 1988-05-11 1994-11-08 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Tracheobronchodilator using 16-substituted PGEs
JP2597649B2 (ja) * 1988-05-11 1997-04-09 株式会社上野製薬応用研究所 気管・気管支拡張剤
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
JPH0791192B2 (ja) * 1989-11-22 1995-10-04 株式会社上野製薬応用研究所 ガス交換機能不全処置剤
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
DK0978284T3 (da) * 1997-11-28 2008-10-27 Sucampo Ag Anvendelse af 15-keto-prostaglandin-E-forbindelser som endothelinantagonister
ATE433754T1 (de) * 2000-04-06 2009-07-15 Sucampo Ag Gallensäurefördernde zusammensetzung für lebertransplantation welche ein 15-keto prostaglandin enthält
JP4786866B2 (ja) * 2001-08-31 2011-10-05 スキャンポ・アーゲー クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
JP5377970B2 (ja) * 2006-02-28 2013-12-25 スキャンポ・アーゲー 慢性閉塞性肺疾患を処置するための方法および組成物
AU2012246999A1 (en) * 2011-04-19 2013-10-17 Sucampo Ag Method for modulating cytokine activity

Also Published As

Publication number Publication date
JP2009528259A (ja) 2009-08-06
AU2007223469B2 (en) 2012-06-07
AR059636A1 (es) 2008-04-16
JP5377970B2 (ja) 2013-12-25
TW200800161A (en) 2008-01-01
JP2013209429A (ja) 2013-10-10
KR101409706B1 (ko) 2014-06-20
EP1988905A2 (en) 2008-11-12
CA2642744A1 (en) 2007-09-13
CN101432002A (zh) 2009-05-13
EP1988905B1 (en) 2014-06-04
MX2008011148A (es) 2008-09-08
WO2007102446A3 (en) 2008-04-03
NZ571092A (en) 2010-11-26
AU2007223469A1 (en) 2007-09-13
WO2007102446A2 (en) 2007-09-13
US20070203228A1 (en) 2007-08-30
KR20080104024A (ko) 2008-11-28
BRPI0708362A2 (pt) 2011-05-24
TWI422368B (zh) 2014-01-11
CN101432002B (zh) 2012-04-04

Similar Documents

Publication Publication Date Title
CA2444103C (en) Composition for treating drug-induced constipation with 15-keto-prostaglandins
AU2002251554A1 (en) Composition for Treating Drug-Induced Constipation
US8530519B2 (en) Method for promoting upper gastrointestinal bicarbonate secretion
JP2597649B2 (ja) 気管・気管支拡張剤
AU2007225798A1 (en) Aqueous composition
EP1988905B1 (en) Method and composition for treating chronic obstructive pulmonary disease
EP2341894B1 (en) Pharmaceutical composition comprising a prostaglandin
JPH0571568B2 (cg-RX-API-DMAC10.html)
US20140066506A1 (en) Method for treating macular degeneration
US20080207759A1 (en) Method for protecting mitochondria
EP0454429B1 (en) Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases
AU2010296307B2 (en) Pharmaceutical combination for treating tumor
US20160120840A1 (en) Method and composition for treating nonerosive reflux disease
JPH03218315A (ja) ガス交換機能不全処置剤

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170227